Renal Cancer - Results from #960

Deregulated expression of the 14q32 miRNA cluster in clear cell renal cancer cells. May 5, 2023

Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States. May 5, 2023

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. May 4, 2023

SAA1 Has Potential as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, and an Indicator for Immune Infiltration of Tumor Microenvironment in Clear Cell Renal Cell Carcinoma. May 4, 2023

STING is a prognostic factor related to tumor necrosis, sarcomatoid dedifferentiation, and distant metastasis in clear cell renal cell carcinoma. May 3, 2023

Low Expression of TSTD2 Serves as a Biomarker for Poor Prognosis in Kidney Renal Clear Cell Carcinoma. May 3, 2023

High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma. May 2, 2023

Candidate variants in DNA replication and repair genes in early-onset renal cell carcinoma patients referred for germline testing. May 2, 2023

Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome. May 1, 2023

Long term experience of robotic retroperitoneal partial nephrectomy as the default approach in the management of renal masses: should the paradigm shift? May 1, 2023

How to manage renal masses in kidney transplant recipients? A collaborative review by the EAU-YAU kidney transplantation and renal cancer working groups. April 28, 2023

Evaluation of Growth Rates for Small Renal Masses in Elderly Patients Undergoing Active Surveillance. April 28, 2023

Radiogenomic associations clear cell renal cell carcinoma: an exploratory study. April 27, 2023

Point of care parenchymal volume analyses to estimate split renal function and predict functional outcomes after radical nephrectomy. April 27, 2023

Comparison between minimally-invasive partial nephrectomy and open partial nephrectomy for complex renal tumors: A systematic review and meta-analysis. April 26, 2023

Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma. April 26, 2023

Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint Inhibitor. April 25, 2023

Identification and verification of prognostic cancer subtype based on multi-omics analysis for kidney renal papillary cell carcinoma. April 25, 2023

Tumor and immune remodeling following radiotherapy in human renal cell carcinoma. April 24, 2023

Clear cell renal cell carcinoma molecular variations in non-Hispanic White and Hispanic patients. April 24, 2023

Page 49 of 456